
Boston Scientific
Advancing science for life™

One coordinated case, from access to closure.

The only concomitant PFA + LAAC approach backed by rigorous clinical evidence



FARAPULSE™ Pulsed Field Ablation Platform

WATCHMAN™ LAAC Implant

Two category leaders. One concomitant approach.

Uniting FARAPULSE™ PFA and WATCHMAN™ LAAC in one setting allows physicians to perform two distinct procedures during the same case and resulting in one patient recovery.

Proven separately.


Leading AFib management technologies FARAPULSE PFA and WATCHMAN LAAC are backed by unmatched independent clinical evidence through studies including ADVENT, MANIFEST-17K and OPTION.



FARAPULSE PFA

- 500,000+ patients treated*
- <1% major adverse event rate[1†]
- Zero cases of thermal injuries[1]
- Short LA dwell time[2,3]
- 250+ clinical trials and publications**

EXPLORE
FARAPULSE PFA DATA



WATCHMAN LAAC

- 800,000+ patients treated*
- 0.2% major adverse event rate[4]
- Non-inferior efficacy, superior safety to OACs post-ablation[5]
- 1,000+ clinical trials and publications**

EXPLORE
WATCHMAN DATA

* BSC data on file.
** Listing of publications and clinical trials on file at BSC.

Now, proven together.

Independent global real-world datasets from ALIGN-AF and COCONUT show consistent outcomes, supporting a combined FARAPULSE PFA and WATCHMAN LAAC case as a safe, feasible concomitant approach for patients eligible for both PFA and LAAC.

Prospective US Registry


ALIGN-AF[6]

n=122 | 12 sites | 24 operators

100% combined procedural success

94.1% no new LAA edema post ablation

90.6% complete seal (0 mm) at 45-90 days



No significant change in LAA orifice diameter



Zero DRT or device shift

Retrospective Global Registry

COCONUT[7]

n=155 | 22 sites | 9 European countries

97.4% combined procedural success

78.1% arrhythmia recurrence-free at 6 months

0 ischemic strokes, DRT or embolization through 6-month follow-up

Procedural efficiency, from access to closure.




ACCESS

VersaCross Connect™ Access Solution for FARADRIVE™ enables zero-exchange left atrial access for FARAPULSE PFA.

1
transseptal puncture[2]

100%
transseptal crossing success[2]



MAP + ABLATE

FARAWAVE™ NAV PFA Catheter and OPAL HDx™ Mapping System integrate mapping, visualization and ablation to reduce catheter exchanges.

69%
zero catheter exchanges in nav-enabled cases[2]

87%
required no additional dedicated mapping catheter[2]



CLOSE

The precision of WATCHMAN TruSteer™ Access System supports optimal WATCHMAN FLX™ Pro LAAC Device placement and enhanced procedural success.

99.3%
procedural success with WATCHMAN TruSteer[8]

81%
reduction in case abort rate[8]

Two procedures. One visit. One patient recovery.

PATIENT JOURNEY

Consult	Pre-op	Procedure	45 days	3–4 mo	6 mo	1 yr	2 yr
• AF evaluation • Shared decision • 3 weeks of uninterrupted anticoagulation pre-procedure	• Labs • CT/TEE	• Undergo concomitant procedure	• Clinic visit • Review AAD regimen	• Post-procedure anti-thrombotic drug regimen per IFU • Post-procedure imaging per IFU	• Telehealth or Office Visit	• Annual follow-up	• Surveillance
CLINICAL WORKFLOW							
• Assess WATCHMAN candidacy	• LAA sizing • Anesthesia	**Perform concomitant PFA+LAAC**	• ECG • Symptom review	• Assess seal/DRT • Rhythm review	• Monitor review	• TEE/CT • Rhythm assessment	• Long-term review

Access & Mapping

- Femoral access
- TSP
- Imaging
- ACT per IFU

FARAPULSE Ablation

- Catheter access
- PVI, additional lesion sets per operator discretion
- Entrance/exit block (optional)

WATCHMAN FLX Pro

- LAA sizing if no pre-screening
- Perform implant
- PASS criteria met

Workflow efficiencies to consolidate costs.

Device cost
ICE, transseptal, access, closure

+

Procedural cost
Cardiology services, imaging, labs, other

=


Total direct duplicated costs
Potential cost savings with concomitant

Contact your Boston Scientific representative for an account-specific economic conversation.


A complete ecosystem shaping the future of AFib care.



FARAWAVE™ NAV PFA Catheter



FARADRIVE™ Steerable Sheath & WATCHMAN TruSteer™ Access System




WATCHMAN FLX™ Pro LAAC Device



VersaCross Connect™ Access Solution for FARADRIVE



FARAVIEW™ Software Module on OPAL HDx™ Mapping System



FARASTAR™ PFA Generator

FARAWATCH™
Concomitant PFA + LAAC

Explore our FARAPULSE PFA + WATCHMAN LAAC concomitant approach at:

bostonscientific.com/concomitant

† MAE data reflect outcomes from a real-world registry. SAE rate of 2.1% observed in the ADVENT Pivotal Trial evaluating the FARAPULSE™ Pulsed Field Ablation System. Source: Reddy, Vivek Y, et al. "Pulsed field or conventional thermal ablation for paroxysmal atrial fibrillation." New England Journal of Medicine 389.18 (2023): 1660-1671.

REFERENCES

1. Ekanem E, Neuzil P, Reichlin T, et al. Safety of pulsed field ablation in more than 17,000 patients with atrial fibrillation in the MANIFEST-17K study. Nat Med (2024). https://doi.org/10.1038/s41591-024-03114-3
2. Rajendra A, et al. (2026). An Integrated Mapping System Improves Procedural Efficiency and Reduces Fluoroscopy in the DISRUPT-AF Registry. Presented at HRS 2026.
3. Badin A, Robinson AK, Farrah A, et al. Comparison of Integrated 3D Electroanatomic Mapping and Conventional Mapping Systems for Pentaspline Pulsed Field Ablation of Atrial Fibrillation. J Cardiovasc Electrophysiol. 2026;37(6) 1353-1355. doi 10.1111/jce.70292.
4. Piccini et al. Poster Presentation. HRS 2025. *Defined as the occurrence of all-cause death, ischemic stroke, systemic embolism, or device or procedure-related events requiring open cardiac surgery or major endovascular intervention between device implantation and seven days or hospital discharge (whichever is later). Includes device or procedure-related events requiring open cardiac surgery or major endovascular intervention such as pseudoaneurysm repair, AV fistula repair or other major endovascular repair.
5. Wazni O, et al. Randomized Comparison of Left Atrial Appendage Closure with Oral Anticoagulation After Catheter Ablation for Atrial Fibrillation. Late Breaking Clinical Trial, American Heart Association 2024.
6. Al-Ahmad A, et al. (2026). Real-World Outcomes of Concomitant Pulsed Field Ablation and Left Atrial Appendage Closure: Acute Safety, Feasibility, and 3 Month Implantation Results from ALIGN-AF. Presented at HRS 2026.
7. Heeger CH, Roten L, Della Rocca D, et al. COnCOmitaNt pulsed field ablation-based pUlmonary vein isolation and lefT atrial appendage closure: the COCONUT study. Europace. 2026;28(9):euag198. doi:10.1093/europace/euag198.
8. Huded C, et al. Procedure Characteristics and Early Clinical Outcomes of Left Atrial Appendage Occlusion Using a Novel Steerable Access System: A Sub-analysis of HEAL-LAA. NY Heart Valves 2025.

Boston Scientific
Advancing science for life™

Boston Scientific Corporation
300 Boston Scientific Way
Marlborough, MA 01752 USA
www.bostonscientific.com

Customer Service
United States: 1-888-272-1001
Canada: 1-888-359-9691

© 2026 Boston Scientific Corporation or its affiliates. All rights reserved.

EP-2526409-AA

WATCHMAN FLX™ Pro Indications, Safety and Warnings
watchman.com/en-us-hcp/watchmanflx-pro-brief-summary.html

FARAPULSE™ PFA System Indications, Safety and Warnings
bostonscientific.com/en-US/products/catheters--ablation/farapulse/farapulse-indications.html